Monographie - Epirubicin hydrochloride

Letztes “update” :
19/11/2024

Epirubicin hydrochloride

Chemische Struktur

Handelsmarke

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Anthracine	Malaysia
Axirubicine	Deutschland
Bendaepi	Deutschland
Binarin	Mexiko
Bioepycina	Polen
Crisabon	Argentinien
Cuatroepi	Argentinien
Ecclepia	Rumänien
Elebicin	Mexiko
Ellence	Vereinigte Staaten von Amerika
Epi Cell	Deutschland
Epidoxo	Argentinien, Chile, Venezuela
Epifil	Ecuador
Epilem	Kolumbien, Mexiko
Epimedac	Deutschland
Epirubicin	Australien, Belgien, Dänemark, Großbritannien, Island, Neuseeland, Österreich, Saudi-Arabien, Schweden, Schweiz, Türkei, Ungarn
Epirubicina	Argentinien, Ecuador, Kolumbien, Mexiko, Rumänien, Spanien
Epirubicine	Belgien, Frankreich, Schweiz
Farmarubicin	Türkei
Farmorubicin	Brasilien, Dänemark, Finnland, Griechenland, Norwegen, Österreich, Saudi-Arabien, Schweden, Schweiz
Farmorubicin CSV	Südafrika
Farmorubicin PFS	Kroatien, Polen, Slowenien
Farmorubicin RD	Brasilien, Polen, russisch, Schweiz
Farmorubicin RTU	Niederlande
Farmorubicina	Brasilien, Italien, Portugal, Spanien
Farmorubicine	Belgien, Frankreich
Pharmorubicin	Großbritannien

Literaturverzeichnis : Epirubicin hydrochloride

	Typ	Veröffentlichung
148	Zeitung	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Zeitung	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Zeitung	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Zeitung	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Zeitung	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Zeitung	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Zeitung	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Zeitung	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Zeitung	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Zeitung	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Zeitung	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Zeitung	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Zeitung	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Labor	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Zeitung	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Labor	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Labor	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Zeitung	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	Poster	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Zeitung	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Zeitung	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales